Today: December 13, 2018, 2:56 pm
  
Business

Endovision’s Single-Use Cholangiogram Guarantees Sterility

Endovision was established in 1987 providing pharmaceutical, medical and surgical companies with specialised niche products, including personalised service to Operating Theatres, laparoscopic and urological surgeons.

 

PR-Inside.com: 2018-02-20 08:03:20
Endovision’s founder Michael Swan has changed the way in which Australian hospitals think about infection control and patient safety in Laparoscopic Cholecystectomy (keyhole surgery removal of the gall bladder). Flushable forceps cannot be internally cleaned due to the complex construction of a tube within a tube and the tiny crevices that could harbour sticky bile and other fluids.


Focusing on safety and looking to reduce costs to hospitals he and his team at Endovision pioneered the single use cholangiogram forceps. The lower priced German instruments and the economical Chinese product in their range makes the single use much more affordable for all.


The Cholangiogram Forceps styles now available from Endovision are Tontarra and Optcla. The company offers Tontarra MAS-007-10, the original and best Single Use Cholangiogram forceps on the Australian market. Designed in Australia and made with German research and development this is widely popular with surgeons. It has been produced by Endovision after extensive research and development with partners in Germany. It manufactures the jaw components to the German-made tubes in Hungary. The assembly and quality control is performed at Tontarra’s facility in Wurmlingen and the final product is shipped to Stuttgart for packaging and sterilising.


Cholangiogram forceps cannot be cleaned. Single use is the only way to eliminate cross infection risks and guarantee sterility for every patient every time. Optcla is the Chinese-made alternative that is more cost effective. The 121-30213 – OPTCLA Cholangiogram Forceps 33cm has a “central ratchet” style. Optcla is part of the extensive Mindray Group and is selling their product around the world.


Michael Swan started work on the flushable cholangiogram forceps in 2006. Working with Tontarra Medizintechnik in Germany he proposed several designs until they agreed on the sixth version which became MAS-006. Working with Tim Cole, Sterilising Services Manager at Concord and Canterbury Hospitals in Sydney, he realised that cholangiogram forceps could not be internally inspected and therefore could not be guaranteed clean.


Endovision designs and sells single use instruments that have proven excellent clinical results. As a leader in their field the company has been working to reduce public risks associated with the use of Cholangiogram Forceps. It also stocks specialised niche products like Sunoptics Surgical, dental headlights, surgical LED headlights, high definition video headlights, surgical video camera, Xenon Lamps, specialised instrumentation and Pos-T-Vac.


To reach Endovision call 03 9550 1819 or email info@endovision.com.au. For more information on surgical equipment and medical instruments supplied by Endovision visit: www.endovision.com.au

Press Information
Endovision
21 Aristoc Road Glen Waverly Victoria 3150 Australia



03 9550 1819
email
www.endovision.com.au

Published by
Cam Wilkes
006499503888
e-mail
www.pureseo.co.nz



# 436 Words
Related Articles
 
More From Business
Aben Provides Final Results from 2018 Drill [..]
VANCOUVER, British Columbia, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Aben Resources Ltd. (TSX-V: ABN) (OTCQB: ABNAF) (Frankfurt: E2L2) (“Aben” [..]
DoubleVerify Launches Brand Safety and Suitability Verification [..]
DV expands its partnership with YouTube to identify off-brand content, enabling measurement of Authentic ImpressionⓇ deliveryNEW YORK, [..]
FROM CUTE TO CONFIDENT: MARY KAY INC. [..]
Mary Kay Inc. and The Museum at The Fashion Institute of Technology Partner for a Pink-Centric Panel Discussion in Conjunction [..]
XBiotech Announces Publication of Post-Hoc Analysis for [..]
Biomarkers Predict Significantly Higher Rates of Treatment Response to Bermekimab in Advanced Cancer PatientsAUSTIN, Texas, Dec. [..]
Orchard Therapeutics Announces the Build-out of New [..]
New facility expected to create more than 100 new jobs, supporting extensive gene therapy pipeline Enhances Orchard’s capacity [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.